This page shows the latest oral octreotide acetate news and features for those working in and with pharma, biotech and healthcare.
The licensing deal - valued at up to $595m - is for Octreolin (oral octreotide acetate), a drug candidate which which is currently in phase III testing for acromegaly and also in development ... Our oral octreotide has the potential to improve the
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...